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Abstract
The efficacy of melphalan (MEL) 140 mg/m2 pre-transplant conditioning versus MEL 200 mg/m2 for the elderly is still debated.
We hypothesized that single-agent intravenous busulfan (BU) would show significant anti-myeloma efficacy and be better
tolerated by elderly patients. A prospective 3þ3 dose escalation study enrolled symptomatic multiple myeloma (MM) patients
65 years or older with SWOG performance 0–2 for treatment with intravenous BU pre-transplant at different administration
levels. The primary objective was to determine the maximum tolerated dose (MTD) of BU that could be safely given over the
least number of days. All patients, except one, received maintenance treatment post-transplant, mostly for 2 years. We
enrolled 13 patients, mean age of 73 years (range 68–80). Pharmacokinetic analysis showed no greater than 2% accumulation in
the 13 patients, confirming a lack of accumulation in the multi-dose regimen. No deaths occurred in the peri-transplant period.
Grade 3/4 adverse effects were hematological, no dose-limiting toxicity was observed and MTD was not reached. Three
patients developed grade 3 mucositis but none developed veno-occlusive disease. Ten (77%) patients achieved a complete
remission (CR) post-transplant with a remarkably long average time to best response of 6.7 months (range: 6–14 m), and two
attained a partial response. Median overall survival was 84 months (95% CI, 21–104) and the median progression-free survival
was 60 months (95% CI, 9–93). Our results suggest that IV BU could be an alternative conditioning regimen to MEL 140 in
elderly patients with MM, and supports future randomized trials.
Keywords
multiple myeloma, busulfan, conditioning regimen

Introduction
Multiple myeloma (MM) is a clonal plasma cell disorder
with significant morbidity and mortality1. High-dose chemotherapy and autologous stem cell transplant continues to
be the standard of care for transplant-eligible patients with
MM. High-dose chemotherapy with autologous stem cell
transplantation is associated with improved response rates
and progression-free survival (PFS) even when compared
with patients treated with a proteasome inhibitor and immunomodulatory imide (IMiD) treatment2,3. Intravenous melphalan at a dose of 200 mg/m2 (MEL 200) is the standard
conditioning regimen for patients receiving autologous stem
cell transplantation for MM. However, elderly patients
treated with MEL 200 have increased treatment-related morbidity and mortality. Badros et al. reported an increase in
transplant-related mortality of 16% with the MEL 200 regimen in patients above 70 years, leading to the recommendation for a dose reduction to 140 mg/m2 (MEL 140) for these

patients4. MEL 140 has become the standard conditioning
regimen for patients aged >70 years or with severe renal
dysfunction. However, there have been no randomized controlled trials comparing these two dose levels and retrospective studies have shown mixed results. In a retrospective
analysis, Saunders et al. compared the outcomes of 63
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patients treated with MEL 140 and 252 patients treated with
MEL 200. Even though overall response rates and PFS were
similar between the two groups, the rates of complete
responses and overall survival were significantly lower for
the MEL 140 group 5 . However, a similar study by
Katragadda et al. on 33 patients with MEL 140 and 96
patients with MEL 200 showed no significant difference in
treatment-related mortality, relapse-free survival or overall
survival between the groups6.
Busulfan is a bifunctional alkylating agent widely used as
a component of conditioning regimens for autologous and
allogeneic stem cell transplantation. Oral busulfan, as a
single-agent conditioning regimen in MM, had an overall
response rate of 46% with three treatment-related deaths of
the 15 patients on the study7. However, oral busulfan showed
significant inter-patient pharmacokinetic variability, and
higher levels have been associated with increased
veno-occlusive disease (VOD) and transplant-related
mortality8–10. The introduction of intravenous busulfan and
therapeutic drug monitoring have ensured safer administration and resulted in tolerable toxicity profiles. Numerous
studies in MM have used both oral and intravenous busulfan
as a conditioning regimen in combination mostly with
melphalan 8,11,12 but also with cyclophosphamide 13,14 ,
idarubicin15, thiotepa16, etoposide17, bortezomib18, carmustine19, and with total body irradiation20. However, singleagent intravenous busulfan with therapeutic dose monitoring
has not been studied as a conditioning regimen for MM.
We hypothesized that single-agent intravenous busulfan
would show significant anti-myeloma efficacy and would
be better tolerated since severe cytopenia occurs later compared with melphalan, while the recovery time is similar,
and in addition, busulfan causes less severe mucositis. If
single-agent busulfan would demonstrate significant antimyeloma activity, it could be used as an alternative conditioning regimen to MEL 140. Therefore, we designed a
phase I/II open-label study of intravenous busulfan in
patients with MM 65 years of age or older receiving autologous stem cell transplantation (ClinicalTrials.gov identifier: NCT00934232). The primary objective of our study
was to determine the maximum tolerated dose (MTD) of
busulfan that can be safely given over the least number of
days to MM patients  65 years of age. Secondary objectives were to perform a pharmacokinetic (PK) analysis to
evaluate the incidence, individual variability of toxicities,
duration of severe cytopenia, and its relationship to each
dose concentration.

Materials and Methods
Patient Population
Patients aged 65 years or older irrespective of renal function
with SWOG performance of 0–2 and symptomatic MM at
the time of initial clinic visit at the Huntsman Cancer Institute requiring treatment were enrolled into the study.
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Patients with a history of chronic obstructive or restrictive
pulmonary disease were excluded from the study. Patients
needed to demonstrate adequate lung function defined as 
50% on FEV1, FVC, and DLCO and adequate cardiac function  40% LVEF on Echo or MUGA scan to be eligible for
the study. Patients were excluded if they had transaminases
>1.5 times the upper limit of normal and/or direct bilirubin >
1.5 times the upper limit of normal; were HIV positive or had
active Hepatitis B or Hepatitis C infection; had a prior autologous or allogeneic bone marrow transplantation; had < 3
million CD34 cells/kg stored; were pregnant or nursing; had
a prior malignancy that affects their life expectancy.
The study was approved by the Institutional Review
Board of the University of Utah (IRB # 32857) and overseen by a data safety monitoring committee. The study
was conducted in according to the Declaration of Helsinki
International Conference on Harmonization and the
Guidelines for Good Clinical Practice. Written informed
consent was obtained from all patients before their enrollment in the study.

Study Design and Treatment
This was a dose escalation study with three patients in each
cohort, at the following dose levels: Cohort I: 3.2 mg/kg for
3 days, Cohort II: 3.2 mg/kg for 4 days, Cohort III: 4.3 mg/kg
for 3 days, Cohort IV: 5.6 mg/kg for 2 days on Day –1 and
Day –3, Cohort V: 5.6 mg/kg for 2 days on Day –1 and Day –
2, Cohort VI: 6.4 mg/kg for 2 days on Day –1 and Day –3,
Cohort VII: 6.4 mg/kg for 2 days on Day –1 and Day –2.
Ideal body weight was used for dose calculation, for males
(kg) ¼ [(height in cmO2.54)–602.3]þ 50, for females(kg)¼[(height in cmO2.54)–602.3]þ 45.5. If the
patient’s actual body weight was greater than 30% of the
ideal weight then adjusted weight was used for dose calculation (Adjusted body weight (kg) ¼ [(actual weight – ideal
weight)0.4] þ ideal weight. Adverse events were scored
according to the NCI CTC, Version 3.0. If no  grade 4 nonhematological toxicity fitting the criteria for serious and
related occurred within 30 days after infusion of the last dose
of busulfan, we proceeded to the next dosing level. If 1/3
patients incurred a  grade 4 non-hematological toxicity that
was serious, and related to the study drug within 30 days
after infusion of the last dose of busulfan, that cohort was
expanded to six patients (i.e., an additional three patients
will be enrolled). MTD was reached if  2/6 experienced
a  grade 4 toxicity (non-hematological) that qualified as
serious and related. If only one of the six patients exhibited a
 grade 4 non-hematologic toxicity considered as being
serious, and related, we proceeded to the next dose level
upon approval of the Principal Investigator and the Data and
Safety Monitoring Committee primary monitor. Responses
were defined according to the International Myeloma Working Group uniform response criteria21.
All patients received busulfan (Busulfex®, Otsuka Pharmaceutical Development & Commercialization, Inc,
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Princeton, NJ, USA) as an intravenous infusion over 6 h
through a central venous catheter using a controlled rate
infusion pump. All patients were admitted to the inpatient
service during busulfan infusion for safety reasons. Peripheral blood stem cell infusion at a dose of  3106 CD34þ/kg
was given intravenously on Day 0 (i.e., approximately 24 h
after the last dose of busulfan but no sooner than 18 h after the
last dose of IV busulfan). In addition to busulfan, dexamethasone was administered at a dose of 20 mg/day on Days –4
until Day –1, and Days þ2 to þ5. All patients received
seizure prophylaxis with either oral phenytoin or fosphenytoin. Phenytoin was loaded with 3 doses of 300 mg PO each
at least 2 h apart, with the last dose to be given a minimum of
1 h before the first dose of IV busulfan; then phenytoin was
given at 300 mg PO once daily for the duration of IV busulfan
administration, plus 1 day after completion of busulfan.
Fosphenytoin was loaded at 1000 mg IV at least 1 h before
starting IV busulfan; then given 300 mg IV once daily for the
duration of IV busulfan administration, plus 1 day beyond the
completion of busulfan. All patients received G-CSF starting
Day 6 after transplantation. All patients received antibacterial, antifungal, antiviral, and anti-Pneumocystis jiroveci
prophylaxis per institutional guidelines.

Determination of PK Data
All busulfan blood samples were drawn from an inserted
peripheral line or PICC line, but not from the port used for
infusion. Samples were collected at baseline prior to the start
of infusion, then at 3 h, 5 h 55 min (before end of infusion
which is the peak sample), 6 h 15 min, 6 h 30 min, 7 h, 8 h,
10 h, 12 h, 18 h, and 24 h (trough sample). Plasma was
separated by centrifugation at 1500 g for 10 min at 4 C.
A complete plasma concentration versus time plot was generated for each subject. Busulfan plasma concentrations
were determined using a previously validated HPLC methodology with UV detection22. Thirteen patients were treated
with a total of 38 doses of busulfan delivered by IV infusion.
A PK profile of concentrations over 24 h was assumed. Raw
PK data from study data were extracted to Excel spreadsheets. Specifically, data required for analysis were
extracted including patient ID, dose, dose number, time of
infusion start, time of infusion end, weight, time of sample
draw, and plasma busulfan concentration

Statistical Analysis
The standard “3þ3”design for dose escalation was applied
with an anticipated enrollment of 30 patients in a maximum
of seven cohorts. Response and toxicity probabilities of
interest could be estimated within +19% with 30 patients
(95% confidence interval). Any toxicity occurring with at
least 10% probability was likely to be observed at least once
in 30 patients (95% or greater probability).
An assessment of busulfan PK parameters was undertaken using a non-compartmental analysis (NCA) approach
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utilizing Phoenix® WinNonlin® version 6.3 (Certara L.P.
(Pharsight, USA), St. Louis, MO). PK parameters were generated using the measured busulfan plasma concentrations
versus time data from each subject. NONMEM (v. 7.3) interfaced with PDx Pop (v. 5.1) was used to develop a base
model to confirm linear pharmacokinetics and investigator
PK compartment structure. The duration of PFS was calculated for all patients from the day of transplantation to the
time of progression, relapse, death from any cause, or reference date (February 1, 2019). Overall survival (OS) was
estimated from the day of transplantation to the date of death
or reference date. PFS and OS were plotted according to the
Kaplan–Meier method. Adverse effects and treatment
responses are presented as mean (+SD) or median values
with 95% confidence intervals. All statistical analysis was
done using GraphPad Prism® (version 7.00 for Windows,
GraphPad Software, La Jolla, CA, USA).

Results
Patient Characteristics
Across five cohorts, we enrolled 13 patients into the study
starting from September 2009 until May 2011 (Table 1). The
average age of the patients in the clinical trial was 73 years
(range 68–80 years). Most had advanced disease, with six of
the 13 patients having ISS II and two having ISS III; for two
patients the initial ISS staging was not available. Most had
standard risk cytogenetic abnormality and only one patient in
cohort 3 had del 17p; this patient had progressive disease and
did not respond to the autologous transplant. Eight patients
had received at least one line of treatment for MM before
transplant. All patients were mobilized with D-PACE except
for one in cohort four who received G-CSF and plerixafor.
Average cell number infused was 7.48 106/kg across all the
different cohorts in the study. As per the institutional policy
at the time of this trial all patients were planned to receive
2 years of maintenance treatment, typically the first year
with VTD (bortezomib 1 mg/m2 on Day 1,4, 15 and 16,
thalidomide 100 mg daily and dexamethasone 20 mg Days
1–4 and 15–18 of a 28 day cycle and the second year thalidomide replaced by cyclophosphamide 500 mg orally on
Days 1 and 15). Patients 1 and 2 in cohort 1 completed
2 years of maintenance with dose adjustments. Patient 3 in
cohort 1 discontinued VTD after 6 cycles due to neuropathy,
switched to lenalidomide/dexamethasone (RD) 15 mg Days
1–21 and continued for total of 2 years with dose adjustments. Patient 1, cohort 2 discontinued VTD after 6 cycles
due to poor tolerance. Patient 2, cohort 2 received VTD
maintenance for 6 months, changed to velcade/lenalidomide/dexamethasone (VRD) for 12 cycles and then completed 1 year of maintenance with dexamethasone 20 mg
Day 1–4 every 3 weeks with dose adjustments. Patient 3,
cohort 2, was switched from VTD to VRD after one cycle,
which was continued for 1 year and then changed to VCD for
second year of maintenance. Patient 1, cohort 3, received
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Table 1. Baseline Characteristics and Different Dose Levels of Busulfan in the 5 Cohorts of 13 Patients Enrolled in the Study. ISS Staging was
not Available for Two Patients. Maintenance Regimens as Noted Given for Two Years Post-Transplant. RD: Revelmid-dexamethasone; VD:
Velcade-dexamethasone; V: Velcade; TD: Thalidomide-dexamethasone; VTD: Velcade-thalidomide-dexamethasone; VRD: Velcaderevlimid-dexamethasone; VCD: Velcade-cyclophosphamide-dexamethasone; (s): Single Agent; Dex: Dexamethsone.

Cohort Bususlfan dose level
I

3.2 mg/kg over 6 h for 3 days

II

3.2 mg/kg over 6 h for 4 days

III

4.3 mg/kg over 6 h for 3 days

IV

5.6 mg/kg over 6 h for 2 days
on Day -1 and Day -3

V

5.6 mg/kg over 6 h for 2 days
on Day -1 and Day -2

Age at
transplant
(years) ISS Cytogenetics

FISH

normal
Trisomy 9,11,15
Trisomy 9,11,15, del 14q
tetrasomy 9,15,
trisomy 11, partial del 14q32
normal
trisomy 9,11,15
normal
hyperdiploid
normal
normal
monosomy 14 17pdel

Pre-transplant

Maintenance
VTD,
VTD,
VTD,
VTD,

72
70
73
80

normal
II normal
II normal
III normal

RD, V (s)
VD
none
Thal dex

79
73
73
80

II
I
I

none
none
RD
TD, RD

73
74
68
68
70

II
II
I
III
II

normal
normal
normal
normal
normal

1q21 gain, hyperdiploid
del13
t;14q32
normal
9q34, 11q13 gain

VCD
VCD
VCD, RD
VCD

VTD, VRD, Dex
VRD, VCD
VTD, VRD
bendamustine Rx
for relapse
RD, Velcade (s) VTD
none
VTD
RD, VTD
VTD, VCD
none
VTD
VTD
VTD, VRD

Figure 1. (A) Representative (Patient 5, cohort 2) concentration-time profile for IV infusion busulfan delivered over *6 h, once daily.
Green line represents the points used for NCA in this patient. (B) Semi-log plot of the elimination phase of the concentration-time (after
dose) profile. Only a single slope is evident, suggesting a one-compartment model may be appropriate.

VTD, but after six cycles was changed to VRD for 3 months
and then RD, but died on treatment. Patient 2, cohort 3 had
progressive disease and did not receive maintenance treatment. Patient 3, cohort 3, received VTD for 1 year with dose
adjustments for thalidomide and dexamethasone and then
lenalidomide single agent 10 mg Day1–21 for 1 year. Patient
1, cohort 4 received only four cycles of VTD maintenance
and was discontinued due to poor tolerance. Patient 2 of
cohort 4 received six cycles of VTD pre-transplant and so
only received six more cycles as maintenance and then

continued VCD for 1 year. Patient 3 of cohort 4 received
six cycles of maintenance and died on treatment. Patient 1,
cohort 5, received four cycles of VTD and four cycles of
VRD but discontinued maintenance due to neuropathy.

Pharmacokinetic Analysis
The first step in this analysis was to ensure that no accumulation of busulfan was occurring. There was an error in the
documentation at the time of analysis for patient ID 3 and
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Table 2. Individual and Mean Non-Compartmental Analysis (NCA) PK Parameters. One Patient in Cohort 1, Patient 3 Had Error in
Documentation of PK Values and so is not Considered in Analysis. Tmax, Time to Maximum Concentration; Cmax, Maximum Concentration;
AUC0!Inf, Area Under the Plasma Concentration-Time Curve Calculated out to Infinite Time; AUClast, Area Under the Plasma
Concentration-Time Curve Calculated to the Last Available Data Point; Vz, Volume of Distribution; CLss, Steady-State Clearance.
Cohort
I

II

III

1V
V
M ean
CV%

Half-Life
(h)

Tm ax
(h)

Cm ax
(mg/L)

2 .21
3 .79
3 .49
3 .2
2 .9
3 .64
2 .88
3 .62
3 .6
3 .39
4 .27
3 .98
3 .42
16 .3

5 .7
5 .92
6 .32
6 .17
6 .23
6 .48
5 .83
6 .15
6 .7
6 .7
6 .47
6 .43
6 .26
5 .2

2
2
2
2
2
4
2
3
5
4
6
4
3
41

.28
.47
.45
.46
.37
.65
.71
.47
.8
.73
.84
.85
.76
.7

therefore this patient was removed from the PK assessments,
leaving full PK data from 12 patients for use in the analysis.
Previously published work23, as well as the PK analysis,
suggested that the half-life of busulfan is 2–3 h. Thus, accumulation was not expected as the 18-h time period between
the end of one infusion, and the initiation of the next represents the passage of at least six half-lives, concurrent with
*99% elimination of the drug. Indeed, a visual examination
of concentration vs. time curves (representative curve,
Fig. 1A) demonstrated no apparent increase in peak concentration (Cpeak) over 2–4 doses. In addition, there was no
greater than 2% accumulation (accumulation index ¼ 1.02)
in the 13 patients, confirming a lack of accumulation in the
multi-dose regimen.
An NCA was performed using the Linear Log Trapezoidal calculation method, with a dosing interval (t) of 24 h,
examination of dose-exposure plots was linear for all
patients. The NCA demonstrated a similar PK profile for
busulfan as has been previously published23, with no accumulation over 2–4 daily doses. Visual examination of the
elimination phase of the concentration vs. time profile on a
semi-log plot (Fig. 1B) appeared to show only a single elimination phase slope, suggesting that a one-compartment
model would provide the best fit. A base model developed
in NONMEM demonstrated a proposed one-compartment
structural model fitted the data the best. PK parameter estimates from the compartmental model were V ¼ 49.2 L, CL
¼ 10.2 L/h. During model development a two-compartment
structural model was also tested; this model did not perform
or fit the data as well. The PK parameter estimates for all the
patients are shown in Table 2. The NCA estimated a mean
steady-state clearance (CLss in L/h) of 9.85, the base onecompartment model estimated a comparable clearance (CL)
of 10.2 L/h.

AUC0 àInf
(h*m g/L)

AUClast
(h*m g/L)

59 .81
75 .73
90 .2
92 .71
91 .04
111 .99
75 .85
74 .71
80 .56
78 .78
127 .25
96 .28
87 .91
20 .7

59 .77
75 .13
89 .13
91 .64
90 .31
111 .51
75 .53
74 .32
79 .66
78 .11
124 .59
95 .12
87 .07
20 .3

Vz
(L)
23
51
41
63
38
47
50
65
59
50
35
51
48
24

.77
.55
.15
.46
.79
.69
.19
.05
.78
.39
.32
.67
.23
.9

CLss
(L/h)
7 .46
9 .42
8 .17
13 .75
9 .28
9 .07
12 .1
12 .45
11 .51
10 .3
5 .73
9
9 .85
23 .2

Safety and Adverse Effects
Most of the grade 3/4 adverse effects were hematological
and no dose-limiting toxicity was observed in the 13 patients
who participated in the study. Grade 3/4 neutropenia
was seen in 2/3 of patients in cohort 1 and 3/3 in all other
cohorts. The average duration of grade IV neutropenia
(ANC <500/mL) was only 3 days (range 1–5 days). The
average time to neutrophil engraftment (defined as the first
of the three days of ANC >500/mL) was 11.5 days (range
10–13 days) with no difference between the different
cohorts. Febrile neutropenia was seen in 1/3 patients in
cohort 1, 4 and 5, 3/3 patients in cohort 2, and none in cohort
3. Grade 3/4 thrombocytopenia was seen in 1/3 patients in
cohort 1 and 2, and 2/3 patients in cohort 4. One patient in
cohort 2 and two patients in cohort 4 required platelet transfusions to keep platelet count >20,000/mL during the posttransplant period. Among the nine patients whose platelet
counts dropped below 50,000/mL during the post-transplant
period, the mean time to platelet recovery to level above
50,000/mL was 15 days post-transplantation (range 12–24
days). One patient each in cohorts 1, 3, 4, and 5, and all three
patients in cohort 2 needed red blood cell transfusion during
the post-transplant period. One patient in cohort 2 who had
previously received 9.17106 CD 34 cells/kg required a
stem cell boost due to poor engraftment. Grade 3 mucositis
was seen in 1/3 patients each in cohort 1, 3, and 5. One
patient in cohort 3 developed grade 4 acute bullous eruptions, thought to be unlikely due to busulfan since the skin
lesions developed outside the 30 day window post-treatment.
Grade 3 or 4 hypocalcemia was seen in three patients, one
each in cohort 1, 2, and 5. None of the patients showed
evidence of VOD of the liver. There were no deaths in the
peri-transplant period and no significant hepatic, pulmonary,

Radhakrishnan et al
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Table 3. Incidence of Grade 3/4 Adverse Events in the Post-Transplant Period Among the 13 Patients in Five Dose Level Cohorts.
Cohort 1
Adverse Events (AE)
Grade 3/4
febrile neutropenia
hypocalcemia
leukopenia
mucositis
neutropenia
thrombocytopenia

Cohort 2

Cohort 3

Cohort 4

Cohort 5

# of
Patients
with AE

% of
Patients
(n¼3)

# of
Patients
with AE

% of
Patients
(n¼3)

# of
Patients
with AE

% of
Patients
(n¼3)

# of
Patients
with AE

% of
Patients
(n¼3)

# of
Patients
with AE

% of
Patients
(n¼1)

1
1
2
1
2
1

33.33
33.33
66.67
33.33
66.67
33.33

3
1
0
0
3
1

100.00
33.33
0.00
0.00
100.00
33.33

0
0
1
1
3
0

0.00
0.00
33.33
33.33
100.00
0.00

1
0
0
0
3
2

33.33
0.00
0.00
0.00
100.00
66.67

1
1
0
1
1
0

100.00
100.00
0.00
100.00
100.00
0.00

Table 4. Treatment Outcomes of 13 Patients After Busulfan
Conditioning and Maintenance Treatment Started at 3 Months
Post-Transplant.
10 (77%)
2 (15%)
1 (8%)
3 (23%)
6.7 m (range 6–14)
60 m (95% CI, 9–93)
84 m (95% CI, 21–104)

100

OS

80

% survival

Complete response
Partial response
Progressive disease
Ongoing complete responses
Mean time to best response
Median progression-free survival
Median overall survival

survival post-transplant

PFS

60
40
20
0

cardiac, or neuronal toxicity. Table 3 lists the common grade
3/4 adverse events of all cohorts in the study.

Efficacy
Ten (77%) patients achieved a CR post-transplant with
an average time to best response of 6.7 months (range:
6–14 months) after transplant (Table 4). One patient in
cohort 3 had progressive disease, and two patients, one each
from cohort 2 and 3, only attained a partial response (PR).
With a median follow-up of 84 months since the transplant,
six (46%) patients are still alive and, of those, three (23%)
continue to be in CR and off all therapy for MM. Median OS
was 84 months (95% CI, 21–104) and the median PFS was
60 months (95% CI, 9–93) (Fig. 2)

Discussion
Even though different conditioning regimens have been
studied, melphalan 200 mg/m2 continues to be the standard
for patients receiving autologous stem cell transplantation
in MM. However, for elderly patients a reduced dose of
140 mg/m2 is the standard of care because of its reduced
toxicity profile, although it is still debated if the lower dose
offers the same efficacy. Busulfan is an alkylating agent used
as a component of conditioning regimens for both autologous and allogeneic stem cell transplantation and has
demonstrated MM efficacy in multi-agent regimens.
In our phase I/II study, busulfan was well tolerated with
no dose-limiting toxicity observed, and all patients on the

0

20

40

60

80

100

120

months
Figure 2. Overall survival (OS) and progression-free survival (PFS)
of 13 patients treated across the five cohorts post-transplant. Median OS was 84 months (95% CI, 21–104) and the median PFS was
60 months (95% CI, 9–93).

study were able to complete the conditioning regimen. All
patients did receive phenytoin prophylaxis and none developed seizures. None of the patients developed VOD of the
liver, which is a well-known toxicity with busulfan. In the
post-transplant period, cytopenia was transient and all
engrafted promptly, except for one patient who needed a
second stem cell infusion. Most patients developed grade
3/4 neutropenia but the duration of severe neutropenia was
very short. Interestingly grade 3/4 thrombocytopenia was seen
in only four of the 13 patients and the platelets recovered to
>50,000/mL at a mean of 15 days compared with 41 days in
previous studies with melphalan4. Grade 3 mucositis was
observed in three patients and was comparable to that observed
in MEL200 in previous studies24, although our patient population was older. The adverse events observed in the posttransplant period and the time to engraftment were similar to
what we would have observed with a melphalan single-agent
conditioning regimen4. Interestingly, even though the study
was open to patients above 65 years, the mean age of the
patients was 73 years, further strengthening the argument that
busulfan at these dosing levels is safe and well tolerated. The
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PK analysis showed no increase in the peak busulfan concentration with multiple day dosing, nor was there any accumulation of busulfan with the repeated dosing. In agreement with
previous studies, the base one-compartment structural model
provided a better fit of the busulfan concentrations than the
two-compartment model. Our model estimated a CL of 10.2
L/h, compared with the literature reported CL estimates which
are higher in adults with value of 12.4 L/h for an equivalent to
70 kg total body weight25. This discrepancy may potentially be
due to a difference in dosing, which was based on ideal body
weight in our study.
Even though no direct comparison was made, patients in
our study had a CR rate of 77%, median PFS of 60 months,
and a median OS of 84 months. This compares favorably
with standard melphalan conditioning regimen which was
reported to provide a CR rate of 49%, median PFS of 28
months, and median OS of 60 months26. However, this is a
phase 1 study with only 13 patients, and no firm conclusions
of therapeutic efficacy in comparison to MEL 140 are possible and efficacy can only be answered by a large randomized trial. Furthermore, it could be argued that the
improvement in survival and response rates seen in our study
was mainly due to the maintenance regimen with bortezomib
and IMiD. However, in the GEM05MENOS65 trial, patients
younger than 65 years with newly diagnosed MM on
Velcade/Thalidomide maintenance given for 3 years after
MEL 200 achieved a CR rate of 21% and PFS of
50.6 months27. Busulfan conditioning combined with maintenance treatment in our study appears to achieve favorable CR
rates and duration of PFS compared with melphalan. Another
particular and probably important observation was that
patients achieved a complete response at a mean of 6.7
months, with one patient attaining a CR 14 months after the
transplant, compared with most patients achieving a CR
within 3 months after MEL 200 transplants28. None of the
long-term survivors who are still in CR have been kept on
treatment after the initial 2 years of post-transplant maintenance. Even though the study did not enroll all the cohorts,
and the numbers in each cohort were small, there appeared to
be no difference among the different dose schedules of busulfan in terms of ability to achieve a CR or duration of response.
A significant shortcoming was that the study did not attain
its anticipated end point of finding the MTD due to the principal investigator leaving the Institution. We did not see any
difference in the limited patients in each cohort, leading us to
believe that busulfan administration over a shorter period of
time and at higher doses per day may very well be feasible.
None of the patients in this study had high risk cytogenetic
abnormality such as t(4:14) or TP53 deletion, except for one.
Therefore, the high CR rates and duration of response could
be due to better disease biology in these patients. However,
most of the patients had a higher stage myeloma (ISS stage II/
III) and had shown progressive disease before transplant.
Our study opens up the possibility of busulfan being used
as an alternative conditioning regimen for autologous stem
cell transplantation with probable benefits in myeloma
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patients above 65 years, and supports larger studies including a randomized trial to see if there is an advantage of IV
busulfan over MEL 140.
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11. Blanes M, Lahuerta JJ, González JD, Ribas P, Solano C, Alegre
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